Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology.
about
Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China.Response to: Second-line treatment of non-small-cell lung cancer with wild-type EGFR status. What is the best approach?
P2860
Is second-line systemic chemotherapy beneficial in patients with non-small cell lung cancer (NSCLC)? A multicenter data evaluation by the Anatolian Society of Medical Oncology.
description
2015 nî lūn-bûn
@nan
2015 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Is second-line systemic chemot ...... n Society of Medical Oncology.
@ast
Is second-line systemic chemot ...... n Society of Medical Oncology.
@en
type
label
Is second-line systemic chemot ...... n Society of Medical Oncology.
@ast
Is second-line systemic chemot ...... n Society of Medical Oncology.
@en
prefLabel
Is second-line systemic chemot ...... n Society of Medical Oncology.
@ast
Is second-line systemic chemot ...... n Society of Medical Oncology.
@en
P2093
P2860
P1433
P1476
Is second-line systemic chemot ...... an Society of Medical Oncology
@en
P2093
Ahmet S Ekinci
Alper Sevinc
Arife Ulas
Dogan Yazilitas
Faysal Dane
Hatice Odabas
Kubra Aydin
Mahmut Gumus
Mehmet Turkeli
P2860
P2888
P304
P356
10.1007/S13277-015-3728-0
P577
2015-07-07T00:00:00Z
P6179
1021365506